Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ILV-094 ADMINISTERED SUBCUTANEOUSLY TO SUBJECT WITH RHEUMATOID ARTHRITIS.

NCT00883896 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00883896
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00883896 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ILV-094 ADMINISTERED SUBCUTANEOUSLY TO SUBJECT WITH RHEUMATOID ARTHRITIS.
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
June 18, 2009
Completion date
February 18, 2011
Enrollment
195 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis